Elliot Wilbur
Stock Analyst at Raymond James
(1.92)
# 3,210
Out of 5,033 analysts
55
Total ratings
33.33%
Success rate
5.34%
Average return
Main Sectors:
Stocks Rated by Elliot Wilbur
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics | Maintains: Strong Buy | $25 → $32 | $14.36 | +122.84% | 8 | May 8, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Outperform | $81 → $83 | $94.79 | -12.44% | 12 | Sep 18, 2024 | |
| SLGL Sol-Gel Technologies | Downgrades: Outperform | $60 → $40 | $40.60 | -1.48% | 8 | Aug 19, 2024 | |
| OGN Organon & Co. | Initiates: Outperform | $33 | $9.28 | +255.60% | 1 | Mar 16, 2023 | |
| PRGO Perrigo Company | Maintains: Outperform | $42 → $43 | $21.62 | +98.89% | 6 | Mar 6, 2023 | |
| PYPD PolyPid | Downgrades: Outperform | $450 → $120 | $3.27 | +3,569.72% | 3 | Sep 6, 2022 | |
| VTRS Viatris | Downgrades: Market Perform | n/a | $10.17 | - | 3 | Mar 1, 2022 | |
| TEVA Teva Pharmaceutical Industries | Downgrades: Market Perform | n/a | $19.31 | - | 4 | Oct 28, 2021 | |
| ZTS Zoetis | Downgrades: Market Perform | n/a | $144.06 | - | 4 | Jul 16, 2021 | |
| ELAN Elanco Animal Health | Initiates: Market Perform | n/a | $21.42 | - | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $7.17 | - | 2 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $23.78 | - | 3 | Nov 9, 2017 |
ADMA Biologics
May 8, 2025
Maintains: Strong Buy
Price Target: $25 → $32
Current: $14.36
Upside: +122.84%
ANI Pharmaceuticals
Sep 18, 2024
Maintains: Outperform
Price Target: $81 → $83
Current: $94.79
Upside: -12.44%
Sol-Gel Technologies
Aug 19, 2024
Downgrades: Outperform
Price Target: $60 → $40
Current: $40.60
Upside: -1.48%
Organon & Co.
Mar 16, 2023
Initiates: Outperform
Price Target: $33
Current: $9.28
Upside: +255.60%
Perrigo Company
Mar 6, 2023
Maintains: Outperform
Price Target: $42 → $43
Current: $21.62
Upside: +98.89%
PolyPid
Sep 6, 2022
Downgrades: Outperform
Price Target: $450 → $120
Current: $3.27
Upside: +3,569.72%
Viatris
Mar 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.17
Upside: -
Teva Pharmaceutical Industries
Oct 28, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $19.31
Upside: -
Zoetis
Jul 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $144.06
Upside: -
Elanco Animal Health
Jan 10, 2020
Initiates: Market Perform
Price Target: n/a
Current: $21.42
Upside: -
Jan 17, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $7.17
Upside: -
Nov 9, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $23.78
Upside: -